Introduction: When to Seek Diagnostic Testing
Recognizing when a child needs diagnostic testing for Mucopolysaccharidosis Type III (also called MPS III or Sanfilippo syndrome) can be challenging because newborns typically appear healthy at birth. This rare genetic condition does not show obvious signs during the earliest months of life, which often leads to delayed diagnosis. However, parents and healthcare providers should consider diagnostic testing when certain warning signs appear during early childhood.[1]
Children who show developmental delays, particularly in speech and language acquisition, between the ages of one and four years old should be evaluated. This is especially important if the delay is accompanied by behavioral problems such as hyperactivity, restlessness, or difficulty sleeping. Parents might notice that their child is not reaching developmental milestones at the expected pace, or that previously learned skills seem to be slipping away.[1][2]
Families with a history of MPS III or similar genetic conditions should seek genetic counseling and consider testing, particularly when planning to have children. Since this condition follows an autosomal recessive inheritance pattern—meaning both parents must carry the faulty gene—couples who are carriers have a 25 percent chance with each pregnancy of having an affected child. In communities where marriages between relatives are common, the risk may be higher.[4][10]
Other early warning signs that warrant medical attention include frequent ear and throat infections, chronic diarrhea, coarse facial features with heavy eyebrows that meet in the middle, mild enlargement of the liver or spleen, and joint stiffness. While these physical features are generally milder in MPS III compared to other forms of mucopolysaccharidosis, their presence alongside developmental concerns should prompt further investigation.[1][3]
Classical Diagnostic Methods
The diagnostic journey for MPS III typically begins with a thorough physical examination by a healthcare provider. During this examination, doctors look for characteristic physical features and assess developmental progress. However, because the physical signs of MPS III can be subtle, especially in young children, laboratory testing becomes essential to confirm the diagnosis.[4][10]
Urine Testing for Glycosaminoglycans
The initial screening test for MPS III is often a urine analysis that measures levels of glycosaminoglycans (GAGs), which are long chains of sugar molecules. In the past, these substances were called mucopolysaccharides, which is where the disease name comes from. People with MPS III have a large amount of a specific type of GAG called heparan sulfate in their urine. When the body cannot properly break down heparan sulfate due to missing or defective enzymes, these molecules accumulate and are excreted in elevated amounts through urine.[4][10][12]
This urine test serves as an important first step because it is non-invasive and relatively simple to perform. If the test shows elevated levels of heparan sulfate, doctors will proceed with more specific diagnostic procedures to confirm the diagnosis and determine the exact type of MPS III.[4]
Blood Enzyme Level Testing
Once elevated heparan sulfate is detected in urine, blood tests are performed to measure the activity levels of specific enzymes. MPS III is caused by deficiencies in one of four different enzymes, and determining which enzyme is affected helps identify the specific subtype of the disease. Type A results from a lack of heparan N-sulfatase enzyme, Type B from insufficient alpha-N-acetylglucosaminidase, Type C from missing or deficient acetyl-CoA:alpha-glucosaminide N-acetyltransferase, and Type D from inadequate N-acetylglucosamine 6-sulfatase.[4][10][12]
These blood enzyme tests are highly specific and can definitively confirm the diagnosis of MPS III. They not only establish that the child has the condition but also identify which of the four subtypes is present. This information is important because Type A tends to be the most severe form, with symptoms appearing earlier and progressing more rapidly than the other types.[4][10]
Skin Fibroblast Culture
In some cases, doctors may perform a skin biopsy to obtain a small sample of skin cells called fibroblasts. These cells are then grown in a laboratory culture and tested to measure enzyme activity. This test can provide additional confirmation of the enzyme deficiency and help distinguish MPS III from other similar conditions. While not always necessary if blood enzyme testing provides clear results, fibroblast culture can be valuable in cases where the diagnosis is uncertain.[4][10]
Genetic Testing
Genetic testing examines the actual DNA to identify mutations in the specific genes responsible for MPS III. The four genes involved are SGSH (for Type A), NAGLU (for Type B), HGSNAT (for Type C), and GNS (for Type D). Finding two faulty copies of one of these genes—one inherited from each parent—confirms the diagnosis. Genetic testing is particularly useful for confirming enzyme test results, identifying carriers in the family, and providing information for prenatal testing in future pregnancies.[1][4][10][12]
The diagnosis of MPS III is established when a person shows suggestive clinical features and laboratory findings, and either has confirmed deficiency of the specific enzyme through blood or fibroblast testing, or has two disease-causing genetic variants identified in one of the four genes.[2]
Additional Diagnostic Tests
Once MPS III is diagnosed, several other tests may be performed to assess the extent of the disease and monitor various body systems affected by the condition. These tests help healthcare providers understand how the disease is impacting different organs and guide supportive care.
An echocardiogram uses ultrasound waves to create images of the heart and check for abnormalities such as weakened heart muscle (cardiomyopathy), irregular heart rhythms (arrhythmia), or problems with heart valves. Since cardiac complications can occur in MPS III, this test helps monitor heart health over time.[4][10][12]
A slit lamp eye examination allows doctors to examine the structures of the eye in detail. This specialized microscope with a bright light helps identify vision problems that may develop as the disease progresses. Regular eye examinations are important because vision problems are common in people with MPS III.[4][10]
X-rays of the bones may reveal skeletal abnormalities known as dysostosis multiplex, a pattern of bone changes seen in mucopolysaccharidosis disorders. These changes might include abnormally shaped bones, joint problems, or issues with growth. However, skeletal features in MPS III are generally less pronounced than in other types of MPS.[1][4]
Hearing tests are conducted because hearing loss is a common problem in MPS III. Regular monitoring of hearing allows for early intervention, which can help with language development and quality of life. Many children with MPS III also experience recurrent ear infections, making hearing assessment particularly important.[2][5]
Prenatal Testing Options
For families who have a child with MPS III or know they are carriers of the gene mutation, prenatal testing is available during pregnancy. Two main procedures can be used: amniocentesis and chorionic villus sampling. Amniocentesis involves collecting a sample of the fluid surrounding the developing baby, usually performed between 15 and 20 weeks of pregnancy. Chorionic villus sampling collects a small sample of placental tissue, typically done between 10 and 13 weeks of pregnancy. Both samples can be tested for enzyme activity or genetic mutations to determine whether the baby has inherited MPS III.[4][10][12]
Diagnostics for Clinical Trial Qualification
As research continues to search for effective treatments for MPS III, various clinical trials are underway testing potential therapies such as gene therapy and enzyme replacement approaches. Participating in these trials requires meeting specific diagnostic criteria to ensure that the study enrolls the right participants and that the results are meaningful.[11]
For clinical trial enrollment, confirmation of MPS III diagnosis through both enzyme deficiency testing and genetic analysis is typically required. Researchers need documented proof that participants have one of the four types of MPS III, established through blood enzyme level measurements showing reduced or absent activity of the specific enzyme, along with genetic testing confirming disease-causing mutations in the corresponding gene (SGSH, NAGLU, HGSNAT, or GNS).[2]
Beyond basic diagnosis, clinical trials often require baseline measurements to track how the disease is affecting various body systems before treatment begins. These baseline assessments typically include urine tests to measure heparan sulfate levels, which serve as a biomarker for disease activity. Throughout the trial, repeated measurements help researchers determine whether an experimental treatment is reducing the accumulation of these harmful substances.[13]
Neurological and developmental assessments are crucial for clinical trials because MPS III primarily affects the brain and nervous system. Researchers use standardized tests to measure cognitive abilities, language skills, motor function, and adaptive behavior. These assessments establish a baseline level of neurological function and help track whether a treatment is slowing down or preventing further decline. Since the disease causes progressive intellectual disability and developmental regression, showing that a treatment can preserve neurological function would be a significant achievement.[2][13]
Brain imaging studies using magnetic resonance imaging (MRI) may be part of clinical trial protocols. MRI scans can reveal structural changes in the brain caused by the accumulation of heparan sulfate and help researchers understand how the disease is progressing. In gene therapy trials, MRI scans might be used to assess whether the therapy is reaching the brain and having the intended biological effects.[7]
Cardiac evaluations including echocardiograms and electrocardiograms (ECG) are often required in clinical trials to ensure participants do not have severe heart problems that could complicate the study. These tests also provide baseline information about heart function, which is important because some experimental treatments might affect the cardiovascular system.[13]
Eligibility criteria for clinical trials often specify the stage of disease progression. Some trials focus on early-stage disease before extensive brain damage has occurred, while others may include participants at various stages. This is because research has shown that starting treatment early, before significant neuronal loss happens, may be more effective. To determine disease stage, trials use a combination of age at diagnosis, developmental assessments, behavioral evaluations, and imaging studies.[11]
Some trials require regular lumbar punctures (spinal taps) to collect cerebrospinal fluid, the liquid that surrounds the brain and spinal cord. This fluid can be analyzed to measure heparan sulfate levels in the central nervous system and assess whether a treatment is reaching its target. While more invasive than blood tests, cerebrospinal fluid analysis provides valuable information about what is happening in the brain.[13]
Quality of life assessments and behavioral questionnaires are increasingly recognized as important outcome measures in MPS III clinical trials. Since behavioral problems, sleep disturbances, and declining abilities significantly impact both patients and their families, researchers want to know whether treatments can improve these aspects of daily life, not just laboratory values.[13][18]
